In earlier studies, we revealed the therapeutic efficacy of MEND for its antiangiogenesis and antitumor effects, by silencing the vegfr2 [31] or biglycan [32] genes in TECs using mouse tumor models. This evidence concerns the gene KDR and neoplasm.